Oguzhan Okcu

Dr. Oguzhan Okcu

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Turkish Journal of Pathology
Verified
Journal Article
Open access
OOOguzhan Okcu
Oguzhan Okcu
BSBayram Sen
Bayram Sen
COCigdem Ozturk
Cigdem Ozturk
GGGulname Findik Guvendi
Gulname Findik Guvendi
RBRecep Bedir
Recep Bedir
Objective: Numerous studies have been conducted to predict the prognosis of breast cancers. The effect of glucose transporter protein 1 (GLUT-1), the main carrier protein responsible for glucose transport, was investigated in breast cancer patients.

1 October 2021 in Annals of Diagnostic Pathology
Verified
Journal Article
Closed access
OOOguzhan Okcu
Oguzhan Okcu
ÇÖÇiğdem Öztürk
Çiğdem Öztürk
BŞBayram Şen
Bayram Şen
MAMedeni ARPA
Medeni ARPA
RBRecep Bedir
Recep Bedir

2 March 2019 in Lasers in Medical Science
Verified
Journal Article
Closed access
PDF file
SASuzan Bayer Alinca
Suzan Bayer Alinca
ESEbru Saglam
Ebru Saglam
NKNur Ozten Kandas
Nur Ozten Kandas
OOOguzhan Okcu
Oguzhan Okcu
NYNergiz Yilmaz
Nergiz Yilmaz
MDMehmet Ali Dogan
Mehmet Ali Dogan

1 September 2019 in Journal of Voice
Verified
Journal Article
Closed access
MYMuhammet Yıldız
Muhammet Yıldız
OYOzgür Yigit
Ozgür Yigit
ASAhmet Volkan Sünter
Ahmet Volkan Sünter
DEDeniz Tuna Edizer
Deniz Tuna Edizer
NDNevra Dursun
Nevra Dursun
OOOguzhan Okcu
Oguzhan Okcu

24 February 2022 in Annals of Diagnostic Pathology
Verified
Journal Article
Closed access
OOOguzhan Okcu
Oguzhan Okcu
SÖSeda Duman Öztürk
Seda Duman Öztürk
ÇÖÇiğdem Öztürk
Çiğdem Öztürk
BŞBayram Şen
Bayram Şen
AYAyşe İrem Yasin
Ayşe İrem Yasin
RBRecep Bedir
Recep Bedir

3 May 2023 in Archives of Pathology & Laboratory Medicine
Verified
Journal Article
Open access
PDF file
NDNevra Dursun
Nevra Dursun
BMBahar Memis
Bahar Memis
BPBurcin Pehlivanoglu
Burcin Pehlivanoglu
OTOrhun Cig Taskin
Orhun Cig Taskin
OOOguzhan Okcu
Oguzhan Okcu
VAVolkan Adsay
Volkan Adsay
Context.—: The nature and associations of gallbladder (GB) “adenomyoma” (AM) remain controversial. Some studies have attributed up to 26% of GB carcinoma to AMs. Objective.—: To examine the true frequency, clinicopathologic characteristics, and neoplastic changes in GB AM. Design.—: Cholecystectomy cohorts analyzed were 1953 consecutive cases, prospectively with specific attention to AM; 2347 consecutive archival cases; 203 totally embedded GBs; 207 GBs with carcinoma; and archival search of institutions for all cases diagnosed as AM. Results.—: Frequency of AM was 9.3% (19 of 203) in totally submitted cases but 3.3% (77 of 2347) in routinely sampled archival tissue. A total of 283 AMs were identified, with a female to male ratio = 1.9 (177:94) and mean size = 1.3 cm (range, 0.3–5.9). Most (96%, 203 of 210) were fundic, with formed nodular trabeculated submucosal thickening, and were difficult to appreciate from the mucosal surface. Four of 257 were multifocal (1.6%), and 3 of 257 (1.2%) were extensive (“adenomyomatosis”). Dilated glands (up to 14 mm), often radially converging to a point in the mucosa, were typical. Muscle was often minimal, confined to the upper segment. Nine of 225 (4%) revealed features of a duplication. No specific associations with inflammation, cholesterolosis, intestinal metaplasia, or thickening of the uninvolved GB wall were identified. Neoplastic change arising in AM was seen in 9.9% (28 of 283). Sixteen of 283 (5.6%) had mural intracholecystic neoplasm; 7 of 283 (2.5%) had flat-type high-grade dysplasia/carcinoma in situ. Thirteen of 283 cases had both AM and invasive carcinoma (4.6%), but in only 5 of 283 (1.8%), carcinoma arose from AM (invasion was confined to AM, and dysplasia was predominantly in AM). Conclusions.—: AMs have all the features of a malformative developmental lesion, and may not show a significant muscle component (ie, the name “adeno-myoma” is partly a misnomer). While most are innocuous, some pathologies may arise in AMs, including intracholecystic neoplasms, flat-type high-grade dysplasia or carcinoma in situ, and invasive carcinoma (1.8%, 5 of 283). It is recommended that gross examination of GBs include serial slicing of the fundus for AM detection and total submission if one is found.